Form 4: Twist Bioscience CEO Sells Shares for Tax Obligations, Not Discretionary Trade

Sentiment:

Insider Transaction Report 10 June 2025 4:05 PM

Twist Bioscience CEO Emily M. Leproust sold 2,170 shares of common stock on June 6, 2025, at $31.75 per share, solely to satisfy tax withholding obligations related to vested Restricted Stock Units.

Summary

Emily M. Leproust, the Chief Executive Officer and a Director of Twist Bioscience Corp. (TWST), reported a transaction on June 6, 2025.
The transaction involved the sale of 2,170 shares of Twist Bioscience common stock at a price of $31.75 per share.
This sale was explicitly stated as a 'sell to cover' transaction, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units.
The filing clarifies that these sales do not represent discretionary trades by the Reporting Person.
Following this transaction, Emily M. Leproust beneficially owns 647,460 shares of common stock.
The filing also details various employee stock options held by Ms. Leproust, including options with exercise prices of $5.95, $8.82, $26.66, $23.33, and $67.85, with varying vesting and expiration dates.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax purposes, not indicative of discretionary selling or a change in sentiment towards the company by the insider. Therefore, it has a neutral impact on sentiment.

Positives

The transaction is a routine 'sell to cover' for tax withholding purposes, which is a standard practice for executives receiving equity compensation and does not indicate a lack of confidence in the company by the CEO.

Negatives

No inherent negatives are identified as the sale was non-discretionary and for tax purposes.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."
"These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person."

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. 'Sell to cover' transactions are a common and expected mechanism for executives to manage tax liabilities arising from the vesting of equity compensation, such as Restricted Stock Units, across various industries.

Stakeholder Impact

Minimal impact on shareholders as this is a routine administrative transaction and not a discretionary sale indicating a change in management's outlook or a significant shift in company strategy.

Key Dates

Date	Description
09/01/2016	Vesting start date for an employee stock option (25% vested, then 1/48th monthly).
09/28/2017	Vesting start date for an employee stock option (10% vested).
09/28/2018	Vesting date for an employee stock option (additional 15% vested, then 1/48th monthly).
10/31/2019	Vesting start date for an employee stock option (20% vested, then 1/60th monthly).
09/01/2020	Grant date for performance stock options.
10/24/2020	Vesting start date for an employee stock option (25% vested, then 1/48th monthly).
12/19/2022	Vesting date for performance stock options upon meeting performance criteria.
06/06/2025	Date of common stock sale transaction.
06/10/2025	Signature date of the Form 4 filing.
09/28/2027	Expiration date for an employee stock option with an $8.82 exercise price.
11/18/2028	Expiration date for an employee stock option with a $26.66 exercise price.
10/23/2029	Expiration date for an employee stock option with a $23.33 exercise price.
08/31/2030	Expiration date for performance stock options with a $67.85 exercise price.

Recommendation

hold

Keywords

Twist Bioscience, TWST, SEC Form 4, Insider Transaction, Stock Sale, CEO, Emily M. Leproust, Restricted Stock Units, Tax Withholding, Equity Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.